Definitive Healthcare (NASDAQ:DH) Issues Q1 2026 Earnings Guidance

Definitive Healthcare (NASDAQ:DH) issued an update on its first quarter 2026 earnings guidance on Thursday morning. The company provided earnings per share guidance of 0.030-0.030 for the period, compared to the consensus earnings per share estimate of 0.050. The company issued revenue guidance of $54.0 million-$56.0 million, compared to the consensus revenue estimate of $57.2 million. Definitive Healthcare also updated its FY 2026 guidance to 0.140-0.170 EPS.

Definitive Healthcare Price Performance

Shares of NASDAQ:DH traded down $0.01 during midday trading on Thursday, reaching $1.40. 753,013 shares of the company’s stock traded hands, compared to its average volume of 372,979. The company has a market cap of $197.91 million, a P/E ratio of -0.84 and a beta of 1.59. The company has a fifty day simple moving average of $2.21 and a two-hundred day simple moving average of $2.89. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.60 and a current ratio of 1.60. Definitive Healthcare has a 1 year low of $1.36 and a 1 year high of $5.22.

Definitive Healthcare (NASDAQ:DH) last posted its quarterly earnings data on Thursday, February 26th. The company reported $0.06 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.06. Definitive Healthcare had a negative net margin of 77.88% and a positive return on equity of 3.30%. The company had revenue of $61.53 million during the quarter, compared to analysts’ expectations of $59.57 million. Definitive Healthcare has set its FY 2026 guidance at 0.140-0.170 EPS and its Q1 2026 guidance at 0.030-0.030 EPS. Equities analysts predict that Definitive Healthcare will post 0.16 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently issued reports on DH shares. Morgan Stanley reiterated an “underperform” rating and issued a $3.50 price objective on shares of Definitive Healthcare in a report on Thursday, December 18th. Barclays lowered their price target on Definitive Healthcare from $3.00 to $2.75 and set an “underweight” rating on the stock in a research note on Monday, December 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Definitive Healthcare in a research report on Wednesday, January 21st. Canaccord Genuity Group decreased their price objective on Definitive Healthcare from $5.00 to $4.00 and set a “hold” rating on the stock in a report on Monday, November 10th. Finally, Wall Street Zen lowered shares of Definitive Healthcare from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 28th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, three have issued a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $3.94.

Key Definitive Healthcare News

Here are the key news stories impacting Definitive Healthcare this week:

• Positive Sentiment: Cash position strengthened — cash and cash equivalents rose to about $163.6M (up ~55% YoY), providing a larger liquidity buffer. Definitive Healthcare Corp. (DH) stock falls on Q4 2025 Earnings
• Positive Sentiment: Revenue roughly in line with expectations — Q4 revenue was about $61.5M, essentially flat YoY and slightly above some estimates, showing demand stability for the data/analytics business. Definitive Healthcare Q4 2025 Press Release / Slide Deck
• Neutral Sentiment: Company filed full Q4 release, slide deck and hosted a conference call — useful for details on customer trends and cost initiatives; review management commentary for color. Q4 Slide Deck / Conference Call
• Negative Sentiment: Guidance disappointed — Q1 EPS guided to $0.03 (vs. consensus ~$0.05) and FY‑2026 EPS guided to $0.14–0.17 (vs. consensus ~$0.21); revenue guidance of $220M–$226M also trails estimates, a main driver of the downward move. Definitive Healthcare Reports Financial Results for Fourth Quarter and Full Fiscal Year 2025
• Negative Sentiment: Profitability metrics mixed/worse in some reports — one summary shows operating loss widening and a larger net loss / diluted EPS miss (Quiver reports diluted EPS -$0.09 and wider losses), which weighed on sentiment; note some sources reported a $0.06 EPS beat — check the company release and call transcript for reconciliation. Definitive Healthcare Corp. (DH) stock falls on Q4 2025 Earnings
• Negative Sentiment: Institutional selling visible — several large funds reduced or exited positions in Q4 (e.g., Palisade, Goldman, NY State Pension), which can amplify downward pressure near-term. Definitive Healthcare Corp. (DH) stock falls on Q4 2025 Earnings

Institutional Investors Weigh In On Definitive Healthcare

Several hedge funds and other institutional investors have recently bought and sold shares of the company. PharVision Advisers LLC acquired a new position in Definitive Healthcare during the third quarter worth $120,000. Creative Planning grew its stake in shares of Definitive Healthcare by 41.7% in the second quarter. Creative Planning now owns 28,628 shares of the company’s stock valued at $112,000 after buying an additional 8,428 shares in the last quarter. Occudo Quantitative Strategies LP purchased a new stake in shares of Definitive Healthcare in the 4th quarter valued at $95,000. Boothbay Fund Management LLC acquired a new position in Definitive Healthcare during the 4th quarter worth about $92,000. Finally, Jain Global LLC purchased a new position in Definitive Healthcare during the 4th quarter valued at about $75,000. 98.67% of the stock is currently owned by institutional investors and hedge funds.

Definitive Healthcare Company Profile

Definitive Healthcare (NASDAQ:DH) is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.

The company’s flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.